This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma And Allergy Awareness Month

BRIDGEWATER, N.J., May 16, 2013 /PRNewswire/ -- Professional football icon Jerome Bettis and Sanofi US, the makers of Auvi-Q™ (epinephrine injection, USP), have teamed up to raise awareness about severe allergic reactions (anaphylaxis) and introduce The Severe Allergy & Anaphylaxis Playbook – a collection of tips to help educate people living with severe allergies, and their friends and family, about avoiding allergens and being prepared in case of an emergency. Bettis, who is severely allergic to shellfish, is encouraging others impacted by severe allergies to download the Playbook and use it in addition to the severe allergy treatment plan they develop with their healthcare provider.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/61041-sanofi-u-s-auvi-q-jerome-bettis-the-severe-allergy-anaphylaxis-playbook

"On the football field it was essential for me to know my plays, and it's no different when it comes to my severe allergy. My game plan is to steer clear of my allergen and in case of accidental exposure, I always carry Auvi-Q, my epinephrine auto-injector, for the emergency treatment of life-threatening allergic reactions. Auvi-Q fits easily in my pocket and like a coach, talks me through the injection process," said Bettis. "Through my work with Sanofi US, I'm hoping to empower others living with severe allergies to equip themselves with smart defensive tactics."

Whether it's covering sugary drinks to avoid insect stings, asking a waiter about ingredients at a restaurant, or sharing an allergy ID card with a teacher – following a few simple steps may help reduce the risk of a severe allergic reaction. The Severe Allergy & Anaphylaxis Playbook offers these tips and many others, including:

  • The Bus' Blitz: Bettis' top five "plays" for defending against a severe allergic reaction
  • Knowing Your Next Move: Strategies for avoiding major allergens, such as food, insect stings, latex and other triggers
  • Away Game Plan: Advice for potentially challenging situations, such as dining out, picnicking, school and traveling

"Several studies indicate that the rate of anaphylaxis has increased in recent years, highlighting the need for continued education on allergen avoidance and the potential life-saving role of epinephrine," said Dr. Vivian Hernandez-Trujillo, a pediatric allergist, national expert in anaphylaxis and consultant to Sanofi US. "I always stress to my patients and their caregivers how important it is to implement appropriate measures for avoiding allergens and to carry an epinephrine auto-injector at all times."

Auvi-Q (epinephrine injection, USP) is the first-and-only epinephrine auto-injector with audio and visual cues for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. The size and shape of a credit card and the thickness of a smartphone, Auvi-Q is a breakthrough in epinephrine auto-injector design that talks patients and caregivers step-by-step through the injection process.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,919.59 +80.85 0.48%
S&P 500 1,981.60 +9.86 0.50%
NASDAQ 4,527.5140 +19.2020 0.43%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs